Navigation Links
Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia
Date:6/13/2008

Compound Inhibits Mutant Forms of BCR-ABL That Cause Resistance to Current

CML and ALL Therapies

COPENHAGEN, Denmark, June 13 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) today reported preliminary phase 1 data from an ongoing trial of XL228 in patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphocytic leukemia (Ph+ALL) who are resistant to or intolerant of the approved BCR-ABL inhibitors imatinib and dasatinib. XL228 is a small molecule inhibitor of BCR-ABL, SRC, and insulin-like growth factor type 1 receptor (IGF1R), which are associated with cancer cell proliferation, survival, and metastasis. The compound also potently inhibits the T315I mutant form of BCR-ABL, which is resistant to all currently approved inhibitors. Dr. Jorge Cortes, Professor of Medicine, Deputy Chair, Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, and an investigator on the phase 1 trial, presented the data in a poster session (Abstract #1260) at the 13th Congress of the European Hematology Association.

Seventeen subjects have received at least one dose of XL228, of whom 16 had completed Cycle 1 as of May 15, 2008. The trial is evaluating a treatment cycle consisting of 4 weekly 1-hour IV infusions of XL228 at doses ranging from 0.45 mg/kg to 7.2 mg/kg. Thirteen of the 17 subjects (76.5%) have BCR-ABL mutations, including seven (41.2%) with the T315I mutation. At the 3.6 and 7.2 mg/kg doses (either as part of Cohorts 4 and 5 or through dose escalation from a previous cohort), all subjects have demonstrated stable or decreasing white blood cell counts. A CML patient with an F317L BCR-ABL mutation in lymphoid blast crisis experienced
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO
2. Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
3. Exelixis Announces First Quarter 2008 Financial Results
4. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
5. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
6. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
7. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
8. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
9. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
10. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
11. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
(Date:7/10/2014)...  Breg, Inc., a premier provider of sports ... knee brace with new innovations to help people, ... to active lifestyles.  FreeRunner,s patent-pending design acts on ... when patients need it most, and the ability ... Patellofemoral issues are the most common cause of ...
(Date:7/10/2014)... , July 10, 2014  RESMED INC. (NYSE: ... quarter and fiscal year ended June 30, 2014 results on ... market close. A press release with ResMed,s results will be ... will host a webcast to discuss operating results and future ... at 1:30 p.m. US Pacific Time and the live webcast ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
(Date:7/11/2014)... Austin, TX (PRWEB) July 11, 2014 ... to their staff. Jim Siddons joins the agency as ... Siddons graduated in 1994 with a Bachelor’s Degree in ... years of industry experience and will manage everything from ... bonds for trucking to the specialized needs for those ...
(Date:7/11/2014)... scientists have been trying to unravel mechanisms that guide ... that generate all blood cells including our immune system. ... because they can only be found in the bone ... a culture dish. Now a group of scientists from ... (Technische Universitt Dresden) was able to generate a mouse ...
(Date:7/11/2014)... July 11, 2014 With the arrival ... men seeking cosmetic surgery and hair transplant procedures, up ... an expansive range of medical tourism destinations, the company ... surgery costs and achieve the look they have ... as the top name in the medical tourism industry, ...
(Date:7/11/2014)... 11, 2014 Fadhits.com, the distinguished wedding ... assortment of lace holiday dresses . To top ... now offered at discounted prices, up to 65% off. ... enjoy this special offer. , Fadhits.com is devoted ... occasion dresses for the global clients. All its items ...
(Date:7/11/2014)... CA (PRWEB) July 11, 2014 Bedros Keuilian ... expert; a title he’s earned by founding the fast-selling fitness ... on marketing their businesses. He works with successful boot camp ... blog post on the traits of the most successful boot ... share three important qualities. , “I’ve worked with and coached ...
Breaking Medicine News(10 mins):Health News:Opening-up the stem cell niche 2Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 2Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 3Health News:Elegant Lace Holiday Dresses Released by Fadhits.com 2Health News:Fitness Boot Camp Marketing Expert Bedros Keuilian Shares the Top Three Traits of Successful Boot Camp Owners 2Health News:Fitness Boot Camp Marketing Expert Bedros Keuilian Shares the Top Three Traits of Successful Boot Camp Owners 3
... The Campaign for Tobacco-Free Kids applauds U.S. Senators Carl ... legislation that gives the U.S. Food and Drug Administration (FDA) ... down on tobacco marketing and sales to kids. The ... The House has approved similar legislation, and Congress is expected ...
... June 11 The following statement of CEO Nancy Brown ... Tobacco Control Act was released today by the American Heart ... bold and courageous step to ensure a healthier future for ... Tobacco Control Act. The legislation will allow us to ...
... Illinois Senators Vote for Historic Bill ... June 11 The Campaign for Tobacco-Free Kids applauds U.S. ... Senate to pass historic legislation that gives the U.S. Food ... the authority to crack down on tobacco marketing and sales ...
... for Tobacco-Free Kids applauds Senate Majority Leader Harry Reid for ... legislation that gives the U.S. Food and Drug Administration (FDA) ... down on tobacco marketing and sales to kids. The ... The House has approved similar legislation, and Congress is expected ...
... June 12, 2009 , , LANCASTER, Pa., June 11 ... financial results for the third quarter ended May 3, 2009. , ... ended May 3, 2009 were approximately $41.8 million, up 25% as ... 2008. , , Income from continuing operations before income taxes ...
... Zix Corporation (ZixCorp(R)), (Nasdaq: ... payor sponsored e-Prescribing services, announced today that it has ... of Directors in investigating strategic alternatives for maximizing the ... review may result in a partnership, joint venture, the ...
Cached Medicine News:Health News:Senators Levin and Stabenow Vote to Protect America's Kids from Tobacco 2Health News:Senator Durbin Leads Fight to Protect America's Kids from Tobacco 2Health News:Senator Durbin Leads Fight to Protect America's Kids from Tobacco 3Health News:Senator Reid Leads Fight to Protect America's Kids From Tobacco 2Health News:Herley Industries, Inc. Reports Third Quarter Earnings 2Health News:Herley Industries, Inc. Reports Third Quarter Earnings 3Health News:Herley Industries, Inc. Reports Third Quarter Earnings 4Health News:Herley Industries, Inc. Reports Third Quarter Earnings 5Health News:Herley Industries, Inc. Reports Third Quarter Earnings 6Health News:Herley Industries, Inc. Reports Third Quarter Earnings 7Health News:Herley Industries, Inc. Reports Third Quarter Earnings 8Health News:Herley Industries, Inc. Reports Third Quarter Earnings 9Health News:Herley Industries, Inc. Reports Third Quarter Earnings 10Health News:Herley Industries, Inc. Reports Third Quarter Earnings 11Health News:Herley Industries, Inc. Reports Third Quarter Earnings 12Health News:Zix Corporation Announces Review of Strategic Alternatives for e-Prescribing Business 2
The Linvatec UltraFix Suture Anchor System's smooth surface until deployed eliminates tissue, bone and suture damage and its ultra smooth eyelet hole preserves suture integrity....
... the industry strives to control costs, Omega ... for patients and providers by manufacturing high ... compact footprint allows installation in a minimal ... quality for identification of the smallest vessels. ...
... Cardiology software increases your office efficiency by ... utilizing a comprehensive cardiology software solution, you ... aspects of your practice and more time ... Lytec is a complete practice solution. With ...
... Practice Management system) allows the entire ... together to deliver the best care ... an Integrated Delivery System (IDS) approach, ... system, enterprise-wide appointment scheduling, referral tracking, ...
Medicine Products: